Exoskeleton - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The exoskeleton market size was valued at USD 0.73 billion in 2025 and is estimated to grow from USD 0.92 billion in 2026 to reach USD 2.35 billion by 2031, at a CAGR of 20.63% during the forecast period (2026-2031). This report is Segmented by Mobility Type (Lower-Body, Upper-Body, Full-Body, Joint-Specific/Waist Systems), Power Source/Mode (Powered/Active, Passive, Hybrid, Soft Exosuits), Body Part (Upper Limb, Lower Limb, Full Body), End User (Hospitals & Rehab Centers, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). Market Forecasts are Provided in Terms of Value (USD).

Global Exoskeleton Market Trends and Insights

Aging Population & Neurological-Disorder Prevalence Boosting Rehab Demand

Worldwide, the cohort aged 60 and above will double to 2.1 billion by 2050, intensifying the incidence of stroke, Parkinson’s disease, and spinal-cord injury. Japanese policymakers widened coverage for Cyberdyne’s HAL in 2024 after data showed that robotic gait therapy shortened the average post-stroke hospital stay by 14 days. Similar evidence is informing European payer pilots, signaling that outcome-based contracts will become the default procurement method for rehabilitation devices. FDA 510(k) clearances and ISO 13482 compliance now serve as baseline requirements for clinic adoption in the United States and the European Union. Together, these trends highlight the enduring demand for lower-limb systems that restore upright mobility, mitigate pressure ulcer risk, and maintain bone density.

Work-Safety Regulations Spurring Industrial Adoption

Revised OSHA guidelines, effective in 2024, oblige U.S. employers to audit overhead tasks and loads above 10 kg, creating a regulatory incentive for shoulder-support rigs. Germany’s Federal Institute for Occupational Safety and Health reported 30-40% reductions in deltoid EMG when workers used passive exoskeletons, prompting automakers to extend deployments across weld, paint, and assembly shops. As insurance premiums fall alongside musculoskeletal disorder claims, factories capitalize on double-digit internal rate of return metrics for upper-body wearables.

High Capital Cost & Limited Reimbursement

Clinic-grade exoskeletons list at USD 80,000-150,000, restricting purchases to academic medical centers or flagship rehabilitation chains. U.S. Medicare requires documented failure of conventional physiotherapy and physician attestation of 30-minute upright tolerance, disqualifying nearly half of potential candidates. Private insurers label take-home models “investigational,” compelling many patients to self-fund despite FDA clearance. Germany reimburses hospital sessions under DRG codes, but refuses to reimburse personal devices, while Italy and France have yet to establish payment pathways. The mismatch depresses adoption in the high-growth home-care segment and reinforces calls for bundled-payment pilots tied to real-world outcome data.

Other drivers and restraints analyzed in the detailed report include:

• Defense Budgets Accelerating Soldier-Augmentation R&D
• Emergence of Mid-Priced Consumer/Outdoor Exosuits Enlarges TAM
• Battery-Energy Density Limits Field Endurance

Segment Analysis

Lower-body rigs held an 87.81% exoskeleton market share in 2025, reflecting their entrenched use in stroke and spinal cord injury rehabilitation, where gait training protocols depend on programmable knee and hip assistance. These units generate steady replacement demand from rehabilitation centers and veterans’ hospitals. In contrast, upper-body systems experienced faster adoption in assembly lines, with a 24.06% CAGR, as automakers and aerospace primes addressed shoulder-injury costs that previously exceeded USD 1 billion annually in lost productivity and compensation claims. Factory pilots validate throughput gains of 15-20% in tasks such as windshield fastening and wing drilling, confirming immediate payback periods. The dual-track dynamic positions lower-limb rigs to dominate clinical revenues while upper-body devices expand industrial revenues and diversify supplier order books.

Upper-body progress aligns with ergonomic mandates now commonly found in U.S. and EU certification audits. Light passive braces weighing under 3 kg win favor for their drop-in compatibility with shift changes, whereas powered shoulder units combine high-peak torque with predictive-maintenance telemetry that reinforces service-contract annuity streams. Full-body exoskeletons remain a niche market for heavy-industry users with handling demands of 90 kg, and joint-specific waist supports are gaining traction in e-commerce distribution centers that face record parcel volumes.

Powered architectures commanded 82.83% of the exoskeleton market size in 2025, necessary for therapeutic gait modulation and soldier-load reduction. Clinics rely on brushless DC motors paired with harmonic drives to deliver 40 Nm of knee torque with sub-50 ms latency, which is vital for neuroplastic rehabilitation. Passive frames, built on springs and cams, excel in overhead factory tasks due to their zero recharge requirements and minimal maintenance. Hybrids integrate passive load-sharing with bright motor bursts, lifting runtime to 8-10 hours and aligning with OSHA-defined shift blocks. Consequently, hybrids are growing at 27.77% CAGR and already dominate new proposal requests from automotive ergonomists.

Battery-intensive powered models still bear regulatory burdens under IEC 60601, while passive frames fall outside many medical device regimes. Vendors now tout firmware that tunes assist curves to user gait data, positioning hybrid exoskeletons as software-defined assets whose performance improves via over-the-air updates. The strategy focuses on recurring-revenue bundles and underpins the subscription leap beyond traditional sales. Suppliers that master torque-to-watt optimization will differentiate themselves as energy density increases, consolidating their share in an increasingly data-rich value chain.

Complete Report Scope:

• By Mobility Type
  • Lower-Body Exoskeletons
  • Upper-Body Exoskeletons
  • Full-Body Exoskeletons
  • Joint-Specific / Waist Systems
• By Power Source / Mode
  • Powered / Active
  • Passive
  • Hybrid
  • Soft Exosuits
• By Body Part
  • Upper Limb
  • Lower Limb
  • Full Body
• By End User
  • Hospitals & Rehab Centers
  • Personal / Home-care Users
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 40.65% of the exoskeleton market share in 2025, driven by FDA-cleared product portfolios and a robust distribution network of durable medical equipment suppliers. The United States leads clinical deployments at centers such as Kessler and Shepherd, where real-world evidence informs payer rule-making. OSHA’s 2024 ergonomic assessment directive is catalyzing factory pilots from Detroit to Seattle, converting EHS compliance budgets into exoskeleton leases. Canada lags due to provincial budget ceilings, whereas Mexico’s nascent market awaits revisions to its social security code to spur reimbursement.

Asia Pacific registers the fastest growth at a 26.87% CAGR through 2031, propelled by China’s 297 million citizens aged 60+ and Japan’s super-aged demographic, where 29% of residents exceed 65 years. Mainland hospitals tap Healthy China 2030 subsidies to order gait-therapy robots, while Japan’s national insurance now reimburses HAL for eight neuromuscular indications. South Korea’s KRW 50 billion robotics fund is nurturing domestic actuator plants that lower bill-of-materials costs. Australia leverages its National Disability Insurance Scheme for pilot grants, and India courts FDI to assemble budget devices for a vast stroke population.

Europe remains bifurcated. Germany, France, and the United Kingdom undertake large-scale industrial pilots under fresh ergonomic directives and secure CE-marked rehab units through DRG codes. Southern Europe lags because fragmented reimbursement hinders capital expenditure planning, and MDR transition timelines strain importer resources. Scandinavia experiments with soft-suit subsidies for rural eldercare, while Eastern Europe focuses EU cohesion funds on stroke rehab capacity. Middle East healthcare hubs in the UAE and Saudi Arabia procure flagship units for showcase hospitals. Still, Africa and South America exhibit limited uptake beyond Brazil’s pilot projects in São Paulo and Rio, which are constrained by tariff regimes and currency fluctuations.

List of Companies Covered in this Report:

• B-Temia
• BIONIK Laboratories Corp.
• Bioness Inc. (Bioventus)
• Bioservo Technologies
• CYBERDYNE Inc.
• Ekso Bionics
• Fourier Intelligence
• Gogoa Mobility Robots
• Lockheed Martin Corporation
• Myomo Inc.
• Ottobock
• Panasonic Corporation
• Parker Hannifin
• RB3D SAS
• ReWalk Robotics
• Rehab-Robotics Co. Ltd.
• Sarcos Technology & Robotics Corporation
• Seismic Powered Clothing
• Wearable Robotics SRL

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support